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Mitochondrial functionHuntington's Disease (HD) is an autosomal dominant neurodegenerative disease caused by a CAG
trinucleotide expansion in the Huntingtin (Htt) gene. The resultant mutant Htt protein (mHtt) forms
aggregates in the brain and several peripheral tissues (e.g., the liver), and causes devastating widespread
pathology. Since aggregates of mHtt have been found in the liver, defects in liver function might contribute to
peripheral abnormalities in HD mice. We previously reported that two crucial transcription factors PPARγ
(peroxisome proliferator-activated receptor-γ) and C/EBPα (CCAAT/enhancer-binding protein α) are
potential therapeutic targets of HD. We herein demonstrate that the transcript level of PPARγ was markedly
downregulated in the livers of a transgenic mouse model of HD (R6/2). Treatment of R6/2 mice with an
agonist of PPARγ (thiazolidinedione, TZD) normalized the reduced PPARγ transcript. By reducing Htt
aggregates and thereby ameliorating the recruitment of PPARγ into Htt aggregates, TZD treatment also
elevated the availability of the PPARγ level and subsequently normalized the expression of its downstream
genes [including PGC-1α (PPAR coactivator-1α) and several mitochondrial genes] and C/EBPα in the liver.
The aforementioned protective effects appeared to be exerted by a direct activation of the PPARγ agonist
(rosiglitazone) because rosiglitazone reduced mHtt aggregates and rescued energy deﬁciency in a hepatoma
cell line (HepG2). These ﬁndings show that the impairment of PPARγ contributes to the liver dysfunction
observed in HD. Treatment with PPARγ agents (TZD and rosiglitazone) enhanced the function of PPARγ, and
might lead to therapeutic beneﬁts.+886 2 28618266.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
HD is an autosomal dominant neurodegenerative disease charac-
terized by motor dysfunction, weight loss, metabolic deﬁcits,
dementia and psychiatric symptoms. The major hallmark of HD is
region-speciﬁc neuronal degeneration in the striatum and cortex,
which subsequently leads to movement disorders and dementia [1,2].
The causative mutation is a CAG trinucleotide expansion in exon 1 of
the Htt gene. The normal Htt gene has 35 or fewer CAG repeats in the
N-terminal region, whereas the appearance of neurological symptoms
is associated with 36 or more CAG repeats in the Htt gene [3]. The
expanded CAG repeat encodes a long polyglutamine tract of Htt which
forms aggregates in the nucleus and/or cytoplasm of affected neurons
in human patients, transgenic animals, and cell lines [4]. Htt is a
protein expressed in almost all tissues. Although most HD symptoms
reﬂect preferential neuronal damage in speciﬁc brain areas, numerous
reports have described additional abnormalities in the peripheral
tissues of HD patients, including progressive body weight loss,diabetes, and sub-cellular abnormalities in lymphocytes and ﬁbro-
blasts [5–8]. Abnormal energy metabolisms (such as hyperglycemia
and lower levels of insulin) were reported in HD patients and
transgenicmousemodels [5,9]. Atrophy of skeletal muscle [10,11] and
dysfunction of adipose tissue [6,12] were also reported in humans and
mice with HD. Since aggregates of mHtt have been found in the mice
livers [13–15], defects in liver function might contribute to HD
pathology. Moreover, urea cycle abnormalities characterized by
hyperammonemia, high blood citrulline, and suppression of urea
cycle enzymes have been reported in twomousemodels of HD [16]. In
a pilot study of 21 HD patients, we also demonstrated that HD patients
exhibited higher blood citrulline levels, suggesting that a urea cycle
deﬁciency might also occur in humans with HD [16]. Changes in
peripheral cells, such as mitochondrial dysfunction, cholesterol
defects, urea cycle deﬁciency, and transcriptional alterations often
resemble abnormalities in the brain and provide valuable insight for
disease mechanisms [10,16–18]. Such defects might result directly
from mHtt expression in peripheral tissues and might be involved in
HD symptoms.
Importantly, transcriptional dysregulation is perhaps the critical
damage caused bymHtt [19]. Htt aggregates have been shown to cause
abnormal protein–protein interactions with a number of transcription
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TAFII130) [16,20–22]. Marked changes in the transcriptional proﬁles
of cells expressing mHtt were therefore, expected and well documen-
ted. Transcriptional and mitochondrial defects are important patho-
genetic mechanisms in both CNS and peripheral pathology in this
disease and could explain many symptoms, such as aggregate
formation, UPS (ubiquitin proteasome system) dysfunction or cell
death. Although the existence of liver Htt aggregates and their
reduction by beneﬁcial treatments have been documented [14–16],
the contribution of hepatic deﬁciencies to HD pathogenesis is
underappreciated. Besides the pathogenic mechanisms mentioned
earlier, bioenergetic defects have been implicated in the pathogenesis
of HD [23]. We earlier showed that expression of mHtt suppresses the
function of a critical transcription factor, C/EBPα [16]. This is of great
interest becausemetabolism deﬁciency is amajor symptomof HD [24]
and C/EBPα is critical for energy homeostasis [25]. The role of
metabolic dysfunction in the progression of HD is therefore of great
interest. Since PPARγ is a major downstream target of C/EBPα, we
hypothesized that the function of PPARγmight also be jeopardized in
HD. Indeed, our recent ﬁndings demonstrated that expression of mHtt
suppresses the transcriptional activity of PPARγ and results in
mitochondrial dysfunction [26]. Moreover, a co-regulator of PPARγ
(PGC-1α) [27] which modulates multiple pathways (including
mitochondrial biogenesis and oxidative phosphorylation) was also
found to be downregulated in HD. It was proposed that a deﬁciency in
PGC-1αmight causemitochondrial dysfunction in HD including brain,
muscle, and fat tissue [10,12,26,28,29].
Dysregulated PPARγ-mediated pathway(s) thus might be attrib-
uted to the pathogenesis of HD. We have been very interested in TZD
as a potential treatment for HD because it is initially identiﬁed as an
agonist of the PPARγ, a transcription factor important for metabolism
and neuroprotection [30,31]. Moreover, Kim et al. [32,33] reported
that major metabolic changes in the liver by PPARγ agonists regulate
hepatic gene expression directly. To assess the functional importance
of the altered expression of PPARγ and its partners (PGC1-α and
C/EBPα) in HD, we treated R6/2 mice with a well-characterized
agonist (TZD) of PPARγ and determined the potential beneﬁcial
effects of HD progression [26]. We thus set out to evaluate the effects of
PPARγ in the livers of R6/2 mice and the mHtt-expressing HepG2 cells.
The treatment of liver defects ameliorated brain pathology and
neurological symptoms in mice with HD [16,34]. Furthermore,
treatment of non-neurological symptoms could improve quality of
life and postpone premature death.
2. Materials and methods
2.1. Animal treatment
Male R6/2 mice and littermate controls were originally obtained
from Jackson Laboratories (Bar Harbor, ME, USA) and mated to female
control mice (B6CBAFI/J), and maintained as previously described [26].
Offspring were identiﬁed by the polymerase chain reaction (PCR)
genotyping and sequencing technique of genomic DNA extracted from
tail tissues using primers located in the transgene (5′-CCGCTC-
AGGTTCTGCTTTTA-3′ and 5′-GGCTGAGGAAGCTGAGGAG-3′). The CAG
repeats of the R6/2 mice used in this study was 217±8 (mean±SEM).
In total, 18 R6/2 transgenic mice and 18 WT littermate controls were
used in this study. Animals were housed at the Institute of Biomedical
Sciences Animal Care Facility under a 12 h light/dark cycle. Animal
experiments were performed under protocols approved by the
Academia Sinica Institutional Animal Care and Utilization Committee,
Taipei, Taiwan. Diets used in the present study were all prepared and
purchased from LabDiet® (Richmond, VA, USA). TZD (Avandia) was
purchased from Smith Klein Beecham (GSK, King of Prussia, PA, USA).
Mice were fed the 0.01% TZD-supplemented diet (1 g TZD prepared in
10 kg LabDiet 5058) from the age of 4 weeks. With the exception of theﬁrst 2 weeks of this diet, duringwhich TZD increased the food intake by
~20%, TZD treatment did not affect the daily food intake as described
earlier [26]. At 12 weeks, liver tissues were collected to determine the
following experiments.
2.2. RNA isolation and quantitative real-time polymerase chain reaction
(PCR)
Total RNA was isolated and reverse-transcribed as detailed else-
where [20]. A real-timequantitativePCRwasperformedusing aTaqMan
kit (PE Applied Biosystems, Foster City, CA, USA) on a StepOne
quantitative PCRmachine (PEApplied Biosystems) using heat-activated
TaqDNA polymerase (Amplitaq Gold; PE Applied Biosystems). C/EBPα,
AS, and AL primer sequenceswere showed as described previously [16].
Other sequences of primers are listed as follows: for PPARγ (5′-AGTTT-
CGATCCGTAGAAGC-3′ and 5′-ATCTTTATTCATCAGGGAGGC-3′), for
PGC1α (5′-AGCCGTGACCACTGACAACG AG-3′ and 5′-GCTGCATGGTT-
CTGAGTGCTAAG-3′), for PGC-1β (5′-CGCTCCAGGAGACTGAATCCAG-3′
and 5′-CTTGACTACTGTCTGTGAGGC-3′), for NRF-1 (5′-GTGGGACAG-
CAAGCGATTGTAC-3′ and 5′-CGCACCACATTCTCCAAAGG-3′), for NRF-2
(5′-TTTTCCATTCCCGAATTACAGT-3′ and 5′-ACCATTTTTACTCA-
TCGATCTCCT-3′), for Tfam (5′-CTGATGGGTATGGAGAAGGAGG-3′ and
5′-CCAACTTCAGCCATCTGCTCTTC-3′), for D-loop (5′-GGAGCACCCT-
ATGTCGCAGTATC-3′ and 5′-TGTCTGTGTGGAAAGTGGCTGTG-3′), for
PPARα (5′-GCAG-CTCGTACAGGTCATCA-3′ and 5′-CTCTTCAT-
CCCCAAGCGTAG-3′), for PPARδ (5′-CTCTTCATCGCGGCCATCATT-3′ and
5′-TCTGCCATCTTCTGCAGCAGC-3′), for Gpx1 (5′-ACAGTCCACC-
GTGTATGCCTTC-3′and 5′-CAGGAGAATGGCAAGAATGAAGAG-3′), for
SOD1 (5′-CAGGACCTCATTTTAATCCTCAC-3′ and 5′-GCA-TGTTGGA-
GACCTGGG-3′), for SOD2 (5′-ATTAACGCGCAGATCATGCA-3′ and
5′-AAGTTCAATGGTGGGGGACA-3′) and for GAPDH (5′-TGACATCAA-
GAAGGTGGTGAAG-3′ and 5′-AGAGTGGGAGTTGCTGTTGAAG-3′). Inde-
pendent reverse-transcription PCRs were performed as described
elsewhere [20]. The relative transcript amount of the target gene,
whichwas calculated using standard curves of serial RNA dilutions, was
normalized to that of GAPDH of the same RNA.
2.3. Filter retardation assay
SDS-insoluble mutant Htt aggregates from the indicated tissues
were retained on OE66membrane ﬁlters (0.2-μmpore size, Whatman
Schleicher and Schuell, Middlesex, UK) through a slot-blot manifold
(Bio-Rad, Irvine, CA, USA), and detected using the appropriate
antibodies (Htt, 1:500; Chemicon International; PPARγ, 1:1000;
Santa Cruz Biotechnology; and PGC-1α, 1:1000 dilution; Cell Signaling
Technology, Danvers, MA, USA; C/EBPα, 1:1000; Santa Cruz Biotech)
as detailed elsewhere [26].
2.4. Western blot assays
Equal amounts of proteinwere separated by sodiumdodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE) using 10% polyacryl-
amide gels according to the method of Laemmli [35]. The resolved
proteins were electroblotted onto Immobilon polyvinylidene diﬂuor-
ide membranes (Millipore, Bedford, MA, USA) for western blot
analyses as reported elsewhere [16]. The primary antibody of
C/EBPα (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
actin (1:3000; Chemicon International), and lamin (1:2000; Santa
Cruz Biotechnology) were utilized as recommended by the corre-
sponding manufacturers.
2.5. Sample preparation and LC/MS/MS method
20 mg of liver tissue were weighed and homogenized using 400 μl
of ice-cold methanol with homogenizer (Precellys 24, Bertin technol-
ogies, Saint-Quentin-en-Yvelines Cedec, FR). Following this, the
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was used to wash the original tube and the liquid was collected and
combined with the homogenate. The mixture was votexed and
centrifuged (13,000g for 15 min at 4 °C). After centrifugation, 690 μl
supernatant was collected, dried with nitrogen and resuspended in
230 μl methanol. The sample was centrifuged again (13,000g for
15 min at 4 °C) then 100 μl supernatant was used for LC–MS analysis.
The ultra performance liquid chromatography-tandem mass spec-
trometry (LC/MS/MS) system [36] consisted an Acquity (Waters,
Milford, MA, USA) coupled to of an APEX Qe Fourier transform ion
cyclotron resonance mass spectrometer equipped with a 9.4 Tesla
superconducting magnet and an Apollo II source (Bruker Dalontonics,
Bremen, Germany). The electrospray ionization in positive mode was
used for detection. Data acquisition and integration were controlled
by Compass apexcontrol 3.0.0 and the data were analyzed by
DataAnalysis 4.0.2.6. Cell culture, plasmid and transfection
HepG2 cells were originally obtained from American Type Culture
Collection (Manassas, VA, USA) and were maintained in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Invitro-
gen) plus 1% penicillin/streptomycin (Invitrogen) in an incubation
chamber gassed with 5% CO2 and 95% air at 37 °C. The day before
transfection, cells were seeded onto a 35-mm dish at a density of
2×105 cells per well. Cells were transfected with Htt constructs
(pcDNA3.1-Htt-(Q)25-hrGFP or pcDNA3.1-Htt-(Q)109-hrGFP [20])
using Lipofectamine 2000 (Invitrogen) for 24 h, and then treated
with the desired reagent(s) for another 48 h. Rosiglitazone and
GW9662 were from Cayman Chemicals (Ann Arbor, MI).2.7. Luciferase assays
Luciferase activities of Htt expressing HepG2 cells were deter-
mined using the Dual-Luciferase Reporter Assay System (Promega) as
described elsewhere [20]. The protein concentrations of lysates were
determined by the Bradford analysis, and the luciferase activities were
normalized to the amount of proteins in the lysate.2.8. Measurement of intracellular ATP concentration
To determine ATP levels, HepG2 cells were collected in a lysis
buffer (0.1 M Tris, 0.04 M EDTA, pH 7.2) and boiled for 3 min. Samples
were then centrifuged (112g for 5 min), and the supernatants were
used in the luciferin/luciferase assay. ATP levels were normalized to
protein content in the samples. Protein concentrations were deter-
mined by the Bradford analysis, and used to calculate protein content
in the amount of samples used for the ATP assay (Promega). The
reaction buffer for this assay contained 60 μM luciferin, 0.06 μg/ml
luciferase, 0.01 M magnesium acetate, 0.05% bovine serum albumin,
and 0.2 M Tris, pH 7.5.Fig. 1. TZD treatment elevated reduced PPARγ and its downstream genes in the livers of
R6/2 mice. Mice were fed the control or 0.01% TZD-supplemented diet from the age of
4 weeks. At the indicated 12 weeks, liver tissues were collected to determine the
transcript levels of PPARγ, PGC1-α, PGC1-β, NRF-1, NRF-2 and Tfam using the Q-PCR
(quantitative real-time PCR) technique. Liver RNA of the mice (n=6 for each
condition) at the age of 12 weeks was collected and reverse-transcribed into cDNA.
Q-PCR technique of the indicated gene was performed and normalized to that of
GAPDH. Values A, B are expressed as percentages of the indicated transcript inWTmice
and are presented as the mean±SEM values from three independent experiments.
Sample sizes for the following experiments are n=6 WT-CON, n=6 WT-TZD, n=6
HD-CON and n=6 HD-TZD. aSpeciﬁc comparison to HD mice fed the control diet
(pb0.001; one-way ANOVA).2.9. Statistical analysis
All data were expressed as means±SEM. To establish signiﬁcance,
data were subjected to unpaired one-way ANOVA using the Sigma
Stat 3.5 software statistical package (Systat SigmaStat V3.5.0.54
Software; San Jose, California, USA). The criterion for signiﬁcance
was set at Pb0.05. Differences between groups were assessed with
Student's t tests or one-way analysis of variance (one-way ANOVA)
as indicated. The signiﬁcance level was set at 0.05 or 0.001 as
indicated.3. Results
3.1. TZD treatment enhanced the reduced expression of PPARγ and its
downstream target genes in the livers of R6/2 mice
A series of protective actions can be triggered in HD through
PPARγ [26]. To rescue the downregulation of the transcript level of
PPARγ in the livers of R6/2mice (Fig. 1A), we treated R6/2micewith a
well-characterized PPARγ agonist (TZD, 0.01%) starting from the age
of 4 weeks for 8 weeks in a form of dietary supplement to activate its
expression. We next determined the expression of a downstream
target gene (PPAR coactivator-1α, PGC-1α) of PPARγ because it has
been implicated in peripheral deﬁcits in the liver, muscle and brown
adipose tissue of HD mice [10,37,38]. Quantitative PCR analyses
revealed that the transcript level of PGC-1α in the livers of R6/2 mice
was much lower than in the WT mice (Fig. 1A). Consistent with the
beneﬁcial effects of TZD on mitochondrial biogenesis [39,40], TZD
signiﬁcantly enhanced the liver level of the PGC-1α gene (Fig. 1A).
Besides, PGC-1α has been implicated in mitochondrial biogenesis
through its ability to control a number of genes such as PGC-1β,
nuclear respiratory factor-1 and factor-2 (NRF-1 and NRF-2) and
mitochondrial transcription factor A (Tfam) [27,41]. Consistent with
the aforementioned ﬁndings, which suggest that the PGC-1α in the
livers of HD mice is impaired, we also found that the mRNA levels of
PGC1-β, NRF-1, NRF-2 and Tfam in the livers of R6/2 mice were much
lower than those in the livers of WT mice. Most importantly, these
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rescued by TZD treatment (Fig. 1).3.2. Expression of mitochondrial, fatty acid metabolic and oxidative
defense genes in the livers of R6/2 mice under TZD treatment
To further evaluate mitochondrial DNA (mtDNA) copy number in
livers of mice, we analyzed the expression of D-loop [42] by
quantitative PCR. We found signiﬁcantly reduced D-loop expression
in R6/2 mice when compared with WT mice (Fig. 2A). TZD treatment
resulted in signiﬁcantly increased D-loop expression in WT mice as
well as in R6/2 mice; however, the degree of D-loop increase was
more pronounced in R6/2 mice. In addition, the PPAR superfamily
contains two other subtypes, PPARα (highly expressed in liver) and
PPARδ (ubiquitous) are involved in fatty acid metabolism [43]. We
also further analyzed the expression of PPARα and PPARδ in livers of
WT and R6/2 mice. No signiﬁcant changes were observed in levels of
PPARα and PPARδ in R6/2 mice under basal conditions when
compared with WT mice (Fig. 2A). Following TZD treatment, PPARα
and PPARδ were also unchanged in livers of WT and R6/2 mice
(Fig. 2A). In addition, several genes [e.g., glutathione peroxidase 1
(Gpx1), superoxide dismutase 1 (SOD-1), and superoxide dismutase 2
(SOD-2)] which mediate the defense mechanism against oxidative
stress are a downstream target of PGC1-α [44]. We found that the
levels of Gpx1 were much lower in the livers of R6/2 mice than those
inWTmice, and TZD signiﬁcantly enhanced their expression (Fig. 2B).Fig. 2. Expression of mitochondrial, fatty acid metabolic and oxidative defense genes in
the livers of R6/2 mice under TZD treatment. Mice were fed the control or 0.01% TZD-
supplemented diet from the age of 4 weeks. At the indicated 12 weeks, liver tissues
were collected to determine the transcript levels of D-loop, PPARα, PPARδ, Gpx1, SOD-
1, and SOD-2 using the Q-PCR technique. Liver RNA of the mice at the age of 12 weeks
was collected and reverse-transcribed into cDNA. Q-PCR technique of the indicated
gene was performed and normalized to that of GAPDH. Values A, B are expressed
as percentages of the indicated transcript in WT mice and are presented as the
mean±SEM values from three independent experiments. Sample sizes for the following
experiments aren=6WT-CON,n=6WT-TZD,n=6HD-CONandn=6HD-TZD. aSpeciﬁc
comparison to HD mice fed the control diet (pb0.05; one-way ANOVA).As shown in Fig. 2B, the expression of SOD-1 and SOD-2 is not
signiﬁcantly reduced in livers of WT and R6/2 mice.3.3. TZD reduced Htt aggregates and ameliorated the recruitment of
PPARγ and PGC1-α by Htt aggregates
As shown in Fig. 3, the livers of R6/2 mice contain Htt aggregates
assessed using the ﬁlter assay with an anti-Htt antibody. The
downregulation of PPARγ and PGC1-α in the livers of R6/2 mice
might have been due to its sequestration by Htt aggregates, because
ﬁlter assays revealed that PPARγ and PGC1-α were detected in Htt
aggregates (Fig. 3). By reducing Htt aggregates upon TZD treatment,
sequestration of PPARγ and PGC1-α were also relieved (Fig. 3). The
TZD-mediated upregulation of PPARγ and PGC1-α in the livers of R6/2
mice may improve mitochondrial biogenesis and lead to protection.3.4. TZD treatment rescued the urea cycle deﬁciency in the livers of R6/2
mice
We also tested the involvement of C/EBPα (a transcription factor
vital for energy homeostasis [25] and urea cycle [16]) because it has
been implicated in the function of PPARγ [45,46]. It is also extremely
interesting to ﬁnd that C/EBPα was recruited into Htt aggregates in
the livers of R6/2 mice, which further reduced the availability of
C/EBPα. By reducing Htt aggregation, TZD treatment partially
prevented the trapping of C/EBPα in Htt aggregates, thus leading to
an elevation in the levels of functional C/EBPα in the liver (Fig. 3).
Indeed, TZD treatment normalized the downregulated transcript and
protein levels of C/EBPα in the HD liver (Fig. 4A and B). In addition,
C/EBPα has been implicated in the urea cycle through its ability to
control a number of genes such as argininosuccinic acid synthetase
(AS) and argininosuccinase acid lyase (AL) [16]. The reducedFig. 3. TZD treatment reduced mHtt aggregates and ameliorated the recruitment of
PPARγ, PGC-1α and C/EBPα by mHtt aggregates. Mice were fed the control or 0.01%
TZD-supplemented diet from the age of 4 weeks. For the ﬁlter-retardation assays, liver
lysates (100 μg per slot) collected from the indicated 12-week-old mice were analyzed.
The insoluble aggregates retained on the ﬁlters were detected using an anti-Htt, anti-
PPARγ, anti-PGC1-α, or anti-C/EBPα antibody. The level of actin in the liver lysate was
assessed using western blot analysis and was used as an internal control. This is one
representative result of the three independent experiments performed (the other two
independent images are shown in Supplementary Fig. S1). Data are presented as the
mean±SEM from three independent experiments Sample sizes for the following
experiments are n=6 WT-CON, n=6 WT-TZD, n=6 HD-CON and n=6 HD-TZD.
aSpeciﬁc comparison to HD mice fed the control diet (pb0.05; one-way ANOVA).
Fig. 4. TZD treatment elevated the levels of C/EBPα and urea cycle enzymes (AS and AL)
in the livers of R6/2 mice. Mice were fed the control or 0.01% TZD-supplemented diet
from the age of 4 weeks. (A) At the indicated 12 weeks, liver tissues were collected to
determine the transcript level of C/EBPα using a Q-PCR technique. The expression levels
of C/EBPα were normalized to that of GAPDH. (B) Nuclear extracts (50 μg) collected
from the livers of the indicated 12-week-old mice were analyzed for the expressions of
C/EBPα, and normalized to a nuclear marker (lamin). (C) The AS and AL transcripts in
the livers of the indicated mice were analyzed using the Q-PCR technique. The
expression levels were normalized to that of GAPDH. Values A, B, C are expressed as
percentages of the indicated transcript inWTmice and are presented as themean±SEM
values from three independent experiments. Sample sizes for the following experiments
are n=6 WT-CON, n=6 WT-TZD, n=6 HD-CON and n=6 HD-TZD. aSpeciﬁc
comparison to HD mice fed the control diet (pb0.05; one-way ANOVA).
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by TZD (Fig. 4C).3.5. Liquid chromatographic tandem mass spectrometric chromatograms
of liver tissues of mice fed TZD
To determine whether TZD treatment affected the pathogenesis of
HD in the liver, we investigated whether TZD reached the liver using
UPLC–tandem mass spectrometry (LC/MS/MS). As shown in Fig. 5,
TZD was detected in liver lysates harvested from R6/2 mice that were
fed the TZD-supplemented diet, but not in animals that were fed the
control diet. TZD is thus likely to exert its protective effect directly in
the liver.3.6. Activation of PPARγ reduced Htt aggregates, normalized reduced
PPRE promoter activity and ATP levels in the mHtt-expressing HepG2
cells
To assess the signal transduction mediating the action of the
PPARγ, a hepatoma cell line (HepG2) was employed for the following
experiments. First, to determine whether stimulation of the PPARγ
had a direct effect on reducing aggregate formation in HepG2 cells,
cells were transfected with an expression construct encoding exon 1
of Htt containing a normal number (25) or an expanded stretch (109)
of CAG repeats fused to hrGFP (designated Htt-(Q)25-hrGFP and
Htt-(Q)109-hrGFP, respectively [20]). Similar suppressive effects of
PPARγ on aggregate formation in vitro or in vivo were observed using
ﬁlter retardation assays. As shown in Fig. 6, treating HepG2 cells with
a PPARγ agonist (rosiglitazone, Rosi) markedly reduced the Htt
aggregates. This effect of Rosi was reversed by an antagonist of PPARγ
(GW9662), demonstrating that the reduction in Htt aggregates by
Rosi in HepG2 cells was mediated by the activation of the PPARγ. By
reducing Htt aggregation, Rosi treatment partially prevented the
trapping of PPARγ in Htt aggregates, thus leading to an elevation in
the levels of functional PPARγ in the mHtt expressing HepG2 cells.
To determine whether the suppression of the function of PPARγ
occurs at the transcriptional level, we used a PPRE-Luc reporter gene,
which contains a PPAR response element [PPRE, [47]]. Relative
to that observed in cells transfected with a control construct (Htt-
(Q)25-hrGFP), expression of polyQ-expanded mHtt (Htt-(Q)109-hrGFP)
in HepG2 cells markedly reduced the expression of the LUC reporter,
which indicated that mHtt suppressed the function of PPARγ (Fig. 7A).
To analyze the consequence of defective mitochondrial biogenesis,
HepG2 cells were employed for the ATP assay. We found that the ATP
level in the Htt-(Q)109-hrGFP expressing cells wasmarkedly lower than
that in the Htt-(Q)25-hrGFP expressing cells (Fig. 7B). Treatment with
Rosi signiﬁcantly enhancedpromoter activity andATP level,whichwere
blocked by GW9662. Thus, Rosi regulates mitochondrial function via a
PPARγ-dependent pathway (Fig. 7A and B). Consistent with the
beneﬁcial effects of TZD on mitochondrial biogenesis, our results
suggest that the activation of PPARγ using agonists (TZD or Rosi) may
rescue the lower function of mitochondria observed in HD via a PPARγ-
dependent pathway.
4. Discussion
PPARγ has previously been implicated in metabolic syndromes
(obesity and hyperglycemia associated with type 2 diabetes mellitus),
stroke and neurodegenerative diseases [30,48,49]. Several genes
involved in glycolysis, glycogen synthesis, lipogenesis, gluconeogen-
esis, and fatty acid oxidation have been identiﬁed as direct targets of
PPARγ [32,33,50]. The beneﬁcial effects of TZD on the metabolic
parameters appeared to be mediated by normalizing the expressions
of PPARγ [26]. The protective role of TZD in mediating the hepatic
protection has not been explored in HD before. In the present study,
we found a lower level of the PPARγ transcript in the livers of R6/2
mice (Fig. 1) and the recruitment of the PPARγ protein into mHtt
aggregates (Fig. 3). These changes might lead to marked suppression
of PPARγ activity by mHtt in the liver and subsequently contribute to
the mitochondrial deﬁciency observed in this devastating disease. To
further evaluate mitochondrial genes in HD, we analyzed the
expression of PGC-1α, its downstream target genes and C/EBPα
involved in mitochondrial function in the liver by quantitative PCR.
The poor PPARγ activity observed in HD led to the inevitable
downregulation of its downstream genes and C/EBPα in the liver
(Figs. 1, 2 and 4). Weakened mitochondrial activity is expected to
exacerbate aggregate formation and to worsen HD progression.
Treatment with TZD signiﬁcantly improved the reduced levels of
hepatic transcriptional factors in the livers of R6/2 mice. Together
with the observation that TZD was detected in the livers of R6/2 mice
Fig. 5. Liquid chromatographic tandemmass spectrometric chromatograms of liver tissues of mice fed TZD. Mice were fed the control or 0.01% TZD-supplemented diet from the age
of 4 weeks. Chromatograms of the liver tissues harvested from the 12-week-old indicated mice were analyzed using the selected ion monitoring mode. Representative
chromatograms are shown. The extracted ion chromatograms of m/z 358.122 ion of (A) TZD, (B) WT-CON, (C) HD-CON, and (D) HD-TZD.
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that TZD exerts an important effect against the toxicity caused by
mHtt in vivo. Our study also demonstrated that reduction in the
available PPARγ protein by recruitment into Htt aggregates is likely to
further impair these metabolic pathways and may contribute to the
systematic dysregulation of energy homeostasis observed in mHtt-
expressing HepG2 cells (Figs. 6 and 7). Our ﬁndings led to the
conclusion that deﬁcient expression of PPARγ is a true phenomenon
that occurs in hepatic cell line expressing mHtt and the livers of HD
mice.
Increasing evidence implicates mitochondrial dysfunction (i.e.,
increased mitochondrial depolarization and early mitochondrial
calcium defects) in HD patients, and mouse models are involved in
energymetabolism defects [18,23,51–55]. Abnormalities inmitochon-
drial function have been observed in lymphoblasts derived from HD
patients [52] and post-mortemHDbrains [56]. Accumulating evidence
from different laboratories suggests that mutant Htt impaired
mitochondrial functions in mutant Htt expressing striatal cells[57,58]. Since PPARγ is vital to mitochondrial stabilization [59],
reduction in the available PPARγ protein by recruitment into Htt
aggregates is likely to further impair the mitochondrial function. Our
ﬁndings are consistent with a recent study demonstrating that
activation of PPARγ by rosiglitazone prevented the mitochondrial
dysfunction in mutant Htt striatal cells [31]. In the present study, we
further demonstrated that the protective effect of TZD occurred in the
livers of R6/2 mice. Here we reported that the TZD treatment reduced
Htt aggregates and therefore ameliorated the hijacking of PPARγ
(Fig. 3). It is also extremely interesting to ﬁnd that PPARγ was
recruited into Htt aggregates in the liver. TZD treatment signiﬁcantly
improved the reduced levels ofmitochondrial numbers and function in
the livers of R6/2mice or inmHtt-expressingHepG2 cells by the PPARγ
pathway. Consistent with our ﬁndings, pioglitazone (a PPARγ agonist)
increased mitochondrial DNA content, levels and activity of electron
transport chain subunits (COX I and IV) in human neuron-like cells
(NT2 cell) [42]. Although only low levels (10–30% of adipose tissue) of
PPARγ mRNA expression in the liver have been reported [60], the
Fig. 6. Rosiglitazone reduced mHtt aggregates and ameliorated the recruitment of
PPARγ by mHtt aggregates in mHtt expressing HepG2 cells. HepG2 Cells were
transfected with pcDNA3-(Htt-(Q)25-hrGFP) or pcDNA3-(Htt- (Q)109-hrGFP) for 24 h,
and then treated with the desired reagents (10 μM rosiglitazone or 20 μMGW9662) for
another 48 h. Lysates (100 μg) harvested from the indicated condition were subjected
to a ﬁlter retardation assay using an anti-Htt and anti-PPARγ antibody. The level of actin
in the cellular lysate was assessed using western blot analysis and was used as an
internal control. This is one representative result of the three independent experiments
performed (other two independent images are shown in Supplementary Fig. S2). Data
are presented as the mean±SEM of at least three independent experiments under each
condition. aSpeciﬁc comparison between the indicated group and that transfected with
pcDNA3-(Htt-(Q)109-hrGFP) with no treatment (pb0.05; one-way ANOVA).
Fig. 7. Rosiglitazone enhanced PPRE promoter activity and ATP level in mHtt expressing
HepG2 cells via the PPARγ pathway. (A) Indicated pcDNA3-(Htt-(Q)25-hrGFP) or
pcDNA3-(Htt-(Q)109-hrGFP) were cotransfected with an PPRE promoter construct into
HepG2 cells for 24 h, and then treated with the indicated reagents (10 μM rosiglitazone
or 20 μMGW9662) for another 48 h. Luciferase activity of each construct was measured
and normalized to the protein content. Values are expressed as percentages of the
promoter activity of PPRE construct in the presence of pcDNA3-(Htt-(Q)25-hrGFP)
under control conditions (no treatment) and are presented as the mean±SEM values
from three independent experiments. (B) HepG2 cells were transfected with pcDNA3-
(Htt-(Q)25-hrGFP) or pcDNA3-(Htt-(Q)109-hrGFP) for 24 h, and then treated with the
indicated reagents (10 μM rosiglitazone or 20 μM GW9662) for another 48 h. Lysates
harvested from the indicated condition were subjected to ATP assay. ATP levels were
normalized to protein content in the samples. Data are presented as the mean±SEM of
at least three independent experiments under each condition. aSpeciﬁc comparison
between the indicated group and that transfected with pcDNA3-(Htt-(Q)109-hrGFP)
with no treatment (pb0.05; one-way ANOVA).
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TZD produces a direct protective effect against the toxicity caused by
mHtt in the liver. Importantly, gene expression proﬁling bymicroarray
suggests that the detectable changes in expression by TZDs are mostly
in the adipocytes [50]. In addition to the actions of PPARγ ligands on
adipose tissue, these compounds exert some of their effects, either
directly or indirectly, on other tissues. In our previous study, we also
demonstrated that the impairment of PPARγ affects the functions of
adipocytes; chronic treatment of R6/2 mice with TZD improved
lipogenesis, elevated the reduced levels of glucose transporter 4 and
normalized hyperglycemia [26]. However, we cannot exclude the
involvement of other tissues (e.g. adipose)which containhigh levels of
PPARγ in the present study. Whether this is a direct TZD activity or
secondary effect from changes in adipocyte physiology requires
further studies using tissue-speciﬁc knockout animals. Nonetheless,
since PPARγ is present in the liver (Fig. 1), a direct effect on its
downstream target is likely to contribute to the beneﬁcial effect we
observed in R6/2 mice.
PGC-1α is a major downstream target of PPARγ, which plays a
critical role in mitochondrial energy demand and glucose metabolism
[27]. It has been demonstrated that PPARγ stimulation, through the
induction of the PGC-1α, promotes mitochondrial biogenesis and
remodeling in several peripheral tissues, such as adipose and muscle
tissues [27]. PGC-1α is a key transcriptional co-regulator that is a vital
mitochondrial function and appears to be involved in HD pathogen-
esis [28]. It also was proposed that a deﬁciency in PGC-1αmight cause
mitochondrial dysfunction in HD including brain, muscle and fat
tissue [10,12,28,29]. Our results showed that activation of PPARγ
enhanced the expression of PGC-1α in the adipocytes, striatum and
livers of R6/2 mice ([26], Fig. 1 of the present study). Indeed, PGC-1α,
which modulates multiple pathways (including mitochondrial respi-
ration, oxidative stress defense, and oxidative phosphorylation, [27]),
was found to be downregulated in HD patients and in several animal
models of HD. This deﬁciency in PGC-1α is believed to cause
mitochondrial dysfunction in the brains of patients and mice with
HD [28,61]. Genetic removal of PGC-1α enhances HD progression, as
assessed by the monitoring of motor coordination and striatal
neurodegeneration [28], which pinpoints the critical involvement ofPGC-1α in HD. We demonstrated in the present study that upregula-
tion of PGC-1α led to a subsequent increase in mitochondrial function
(Figs. 1 and 7) and probably rescued a wide variety of mechanisms
that suffered from energy deﬁciency in HD. By upregulating PGC-1α,
TZD treatment normalized the activity of the mHtt-damaged
mitochondrial function and delayed HD progression.
Consistent with our recent ﬁndings in the striatum [26], we
reported in the present study that TZD reduced Htt aggregates and
therefore mitigated the hijacking of PGC-1α (Fig. 3). PGC-1α plays a
prominent role in regulating mitochondrial biogenesis and cellular
respiration by modulating the expression of transcription factors
NRF-1 and NRF-2, which regulate nuclear-encoded mitochondrial
genes such as Tfam, and are essential for mitochondrial DNA
replication and the levels of the respiratory chain complexes [27,62].
Another family member (PGC-1β), also known to regulate important
aspects of mitochondrial content, energy demand and respiratory
enzymes [63,64], might also be involved in mitochondrial function. In
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NRF-1, NRF-2, and Tfam) of PGC-1α might contribute to the
mitochondrial dysfunction of HD. Moreover, PGC-1α and PGC-1β
activate the expression of PPARα target genes involved in the liver and
might serve as key regulators of lipid metabolism [65,66]. It is not
surprising that PPARα knock-out mice develop fatty livers and
steatohepatitis [67]. No signiﬁcant changes were observed in levels
of PPARα and PPARδ in WT and R6/2 mice (Fig. 2A), indicating no
developed hepatic steatosis with accumulation of lipids in the liver.
Accordingly, Chaturvedi and co-workers recently reported insigniﬁ-
cant change in hepatic morphology in anothermousemodel HD (NLS-
N171-82Q) under basal conditions when compared with WT mice
[37]. Interestingly, energy-deprivation in NLS-N171-82Q mice caused
morphological abnormalities in their livers with accumulation of
neutral lipids [37].
We previously reported that the urea cycle deﬁciency character-
ized by hyperammonemia, high blood citrulline, and suppression of
urea cycle enzymes is a prominent feature of HD mice [16]. The
underlying mechanism is the suppression of C/EBPα by mHtt. C/EBPα
is highly expressed in the liver [68] and regulates many genes (as in
the urea cycle and gluconeogenesis) that are preferentially expressed
in the liver [69]. Indeed, Inoue et al. [70] reported that hepatic C/EBPα
is critical for ammonia detoxiﬁcation, glucose metabolism, and lipid
homeostasis, indicating that C/EBPα plays an important role in
maintaining liver metabolic functions. The previous studies demon-
strated that cells lacking PPARγ express reduced levels of C/EBPα
[45,46]. We tested the involvement of C/EBPα in HD because it has
been implicated in the apparent liver deﬁciency and thus might
facilitate the design of a proper treatment for HD. Our results revealed
that suppression of C/EBPα for the urea cycle [69] might mediate the
urea cycle deﬁciency which is an important factor in the pathogenesis
of HD, and contributes to the disease progression. Since Htt
aggregation has been found in the liver [14,71], it is plausible that
Htt aggregation in the liver may cause liver dysfunction and trigger
hyperammonemia. Hyperammonemia can result from genetic defects
of urea cycle enzymes and transporters of amino acids related to the
urea cycle, or other metabolic abnormalities and liver failure [72]. We
set out to identify the target enzymes (AS and AL) of the urea cycle
that might be altered by mHtt and were responsible for urea cycle
deﬁciency, supporting the possibility that expression of mHtt with
expanded polyQ might affect the function of the liver. In the present
study, we show that TZD, which activates the PPARγ, improves the
liver function.
Importantly, post-mortem livers of HD patients show signiﬁcant
atrophy and pathology which are consistent with abnormal liver
functions [73,74]. Morphologically, the livers of R6/2 mice appeared
normal, except that the livers of R6/2 mice exhibited Htt aggregates,
morphologically similar to those typically seen in brain tissue, but
never seen in livers from WT mice [16]. A recent study demonstrated
that circadian rhythms of clock-driven genes, which are keymetabolic
outputs in the liver, are abolished in R6/2 mice [75]. Dysregulation of
circadian metabolic genes (Ass1 and Arg1), key elements of the urea
cycle, is like to cause the accumulation of ammonia [76,77] and
aggravate HD neuropathology. The notion that liver and neuronal
pathology are linked is supported by our previous reports that urea
cycle abnormalities characterized by hyperammonemia have been
shown in two mouse models of HD [16,34]. This is important because
hyperammonemia has been implicated in excitotoxicity, a major
pathogenic mechanism underlying neuronal damage in HD [78,79]. In
addition, raised ammonia levelsmodify glutamate receptor function to
cause excitotoxicity and mitochondrial dysfunction [79,80]. These
reports are consistent with our view that ammonia toxicity might
contribute to the progression of HD. Because of the importance of
PPARγ in the metabolic pathways (including C/EBPα mediated urea
cycle and PGC-1α regulatedmitochondrial function) [27,39,45,46], we
hypothesize that reduced PPARγ and PGC-1α inHD are likely to lead tomultiple deﬁciencies in peripheral metabolic pathways. In particular,
recent evidence has demonstrated that PGC-1α expression and
PGC-1α signaling are downregulated both in neuronal and peripheral
tissues (including liver, fat and muscle) of HD animal models
[10,12,37]. Overall these data strengthen the hypothesis that bioen-
ergetic defects occur and associate in brain and peripheral tissues of
HD. We suggest that agonists of PPARγ (thiazolidinedione or
rosiglitazone) reduced mHtt aggregates, ameliorated the recruitment
of hepatic transcriptional factors, elevated reduced PPARγ and its
downstream genes in the livers of R6/2 mice, suggesting a potential
overlap of the underlying mechanism.
5. Conclusions
These recent ﬁndings suggest that HD treatments which simulta-
neously ameliorate defects in both the central nervous system (CNS)
and peripheral tissues are likely to be more effective than those that
only normalize dysfunctions in the CNS [81]. Transcriptional and
mitochondrial defects are important pathogenetic mechanisms in
both CNS and peripheral pathology in this disease and could explain
many symptoms, such as aggregate formation, UPS dysfunction, ER
(endoplasmic reticulum) stress or cell death. Although the existence
of liver Htt aggregates and their reduction by beneﬁcial treatments
have been documented [14–16], the contribution of hepatic deﬁcien-
cies to HD pathogenesis is underappreciated. Dysregulated PPARγ-
mediated pathway(s) in the liver thus might be attributed to the
pathogenesis of HD. Furthermore, these R6/2 mice and mHtt
expressing cells might be useful models to understand the hepatic
function of PPARγ and establish a possible search for therapeutic
targets. Our results provide insights into the potential role of PPARγ in
HD, and might facilitate the development of therapeutic treatments
for HD.
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